Literature DB >> 10722532

Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distant dream or near reality?

D M Yellon1, G F Baxter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10722532      PMCID： PMC1729364          DOI： 10.1136/heart.83.4.381

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  40 in total

Review 1.  The Na-H exchanger revisited: an update on Na-H exchange regulation and the role of the exchanger in hypertension and cardiac function in health and disease.

Authors:  O Frölich; M Karmazyn
Journal:  Cardiovasc Res       Date:  1997-11       Impact factor: 10.787

2.  Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor.

Authors:  H Yaoita; K Ogawa; K Maehara; Y Maruyama
Journal:  Circulation       Date:  1998-01-27       Impact factor: 29.690

3.  Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection.

Authors:  K D Garlid; P Paucek; V Yarov-Yarovoy; H N Murray; R B Darbenzio; A J D'Alonzo; N J Lodge; M A Smith; G J Grover
Journal:  Circ Res       Date:  1997-12       Impact factor: 17.367

4.  Evidence for a role for both the adenosine A1 and A3 receptors in protection of isolated human atrial muscle against simulated ischaemia.

Authors:  C S Carr; R J Hill; H Masamune; S P Kennedy; D R Knight; W R Tracey; D M Yellon
Journal:  Cardiovasc Res       Date:  1997-10       Impact factor: 10.787

5.  Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family.

Authors:  M Endres; S Namura; M Shimizu-Sasamata; C Waeber; L Zhang; T Gómez-Isla; B T Hyman; M A Moskowitz
Journal:  J Cereb Blood Flow Metab       Date:  1998-03       Impact factor: 6.200

6.  Myocardial protection afforded by nicorandil and ischaemic preconditioning in a rabbit infarct model in vivo.

Authors:  J Imagawa; G F Baxter; D M Yellon
Journal:  J Cardiovasc Pharmacol       Date:  1998-01       Impact factor: 3.105

7.  Ischemic preconditioning and morphine-induced cardioprotection involve the delta (delta)-opioid receptor in the intact rat heart.

Authors:  J J Schultz; A K Hsu; G J Gross
Journal:  J Mol Cell Cardiol       Date:  1997-08       Impact factor: 5.000

8.  Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularization.

Authors:  D J Patel; H J Purcell; K M Fox
Journal:  Eur Heart J       Date:  1999-01       Impact factor: 29.983

9.  TAN-67, a delta 1-opioid receptor agonist, reduces infarct size via activation of Gi/o proteins and KATP channels.

Authors:  A K Hsu; H Nagase; G J Gross
Journal:  Am J Physiol       Date:  1998-03

Review 10.  Cardioprotection by ACE inhibitors in myocardial ischaemia/reperfusion. The importance of bradykinin.

Authors:  G Heusch; J Rose; T Ehring
Journal:  Drugs       Date:  1997       Impact factor: 9.546
View more
  27 in total

1.  Harnessing the preconditioning phenomenon: does remote organ ischaemia provide the answer?

Authors:  A Burdess; D Newby
Journal:  Heart       Date:  2005-09-13       Impact factor: 5.994

2.  Rationale of the REPARATOR study: A randomised trial with serial cardiac MRI follow-up testing the ability of atorvastatin to reduce reperfusion damage after primary PCI for acute MI.

Authors:  F D Eefting; M J Cramer; P R S Stella; B J Rensing; P A Doevendans
Journal:  Neth Heart J       Date:  2006-03       Impact factor: 2.380

3.  Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury.

Authors:  M M Mocanu; G F Baxter; D M Yellon
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

4.  Impaired perfusion after myocardial infarction is due to reperfusion-induced deltaPKC-mediated myocardial damage.

Authors:  Fumiaki Ikeno; Koichi Inagaki; Mehrdad Rezaee; Daria Mochly-Rosen
Journal:  Cardiovasc Res       Date:  2006-12-13       Impact factor: 10.787

5.  Role of nuclear factor-kappa B activation in acute ischaemia-reperfusion injury in myocardium.

Authors:  Adrienn Kis; Derek M Yellon; Gary F Baxter
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

6.  Relation of the ischaemic substrate to left ventricular remodelling by cardiac magnetic resonance at 1.5 T in rabbits.

Authors:  Nicolas Mansencal; Renaud Tissier; Jean-François Deux; Bijan Ghaleh; Nicolas Couvreur; Mario Rienzo; Pascal Guéret; Alain Rahmouni; Alain Berdeaux; Jérôme Garot
Journal:  Eur Radiol       Date:  2009-11-21       Impact factor: 5.315

7.  Technetium-99m pyrophosphate/thallium-201 dual-isotope SPECT imaging predicts reperfusion injury in patients with acute myocardial infarction after reperfusion.

Authors:  Yasushi Akutsu; Kyouichi Kaneko; Yusuke Kodama; Hui-Ling Li; Hideki Nishimura; Yuji Hamazaki; Jumpei Suyama; Akira Shinozuka; Takehiko Gokan; Youichi Kobayashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09-12       Impact factor: 9.236

Review 8.  Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling.

Authors:  D S Burley; P Ferdinandy; G F Baxter
Journal:  Br J Pharmacol       Date:  2007-08-13       Impact factor: 8.739

Review 9.  Fibroblast growth factor-2 and cardioprotection.

Authors:  Elissavet Kardami; Karen Detillieux; Xin Ma; Zhisheng Jiang; Jon-Jon Santiago; Sarah K Jimenez; Peter A Cattini
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

10.  The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion.

Authors:  Borja Ibanez; Giovanni Cimmino; Susanna Prat-González; Gemma Vilahur; Randolph Hutter; Mario J García; Valentin Fuster; Javier Sanz; Lina Badimon; Juan J Badimon
Journal:  Int J Cardiol       Date:  2009-11-12       Impact factor: 4.164
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.